59,117 results match your criteria Psoriasis

Association of S100A8/A9 with lipid-rich necrotic core and treatment with biologic therapy in patients with psoriasis: results from an observational cohort study.

J Invest Dermatol 2022 Jun 21. Epub 2022 Jun 21.

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Electronic address:

Psoriasis is a systemic inflammatory disease with increased risk of atherosclerotic events and premature cardiovascular disease. S100A7, A8/A9, and A12 are protein complexes that are produced by activated neutrophils, monocytes, and keratinocytes in psoriasis. Lipid-rich necrotic core (LRNC) is a high-risk coronary plaque feature previously found to be associated with cardiovascular risk factors and psoriasis severity. Read More

View Article and Full-Text PDF

Potential shared therapeutic and hepatotoxic mechanisms of Tripterygium wilfordii polyglycosides treating three kinds of autoimmune skin diseases by regulating IL-17 signaling pathway and Th17 cell differentiation.

J Ethnopharmacol 2022 Jun 21:115496. Epub 2022 Jun 21.

Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, 210042, China. Electronic address:

Ethnopharmacological Relevance: Tripterygium wilfordii polyglycosides (TWP) are extracted from Tripterygium wilfordii Hook. f., which has the significant effects of anti-inflammation and immunosuppression and has been widely used to treat autoimmune diseases in traditional Chinese medicine. Read More

View Article and Full-Text PDF

DPP-4 inhibitor linagliptin ameliorates imiquimod-induced psoriasis-like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF-κB inflammatory pathway.

Drug Dev Res 2022 Jun 24. Epub 2022 Jun 24.

Department of Endocrinology, 900 Hospital of the Joint Logistics Team, Fuzong Clinical Medical College of Fujian Medical University, Fujian, Fuzhou, China.

Studies have shown that the DPP-4 inhibitor was effective in improving skin damage in patients with psoriasis, but the exact mechanism was not known. To investigate the therapeutic effects of linagliptin in mice with type 2 diabetes mellitus (T2DM) with psoriasis and its possible therapeutic mechanisms. A total of 32 db/db mice and 16 db/m mice were randomly divided into six groups: normal group, psoriasis group, diabetes group, diabetes combined with psoriasis group, linagliptin-treated diabetes group, and linagliptin-treated diabetes combined with psoriasis group. Read More

View Article and Full-Text PDF

Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study.

Ocul Immunol Inflamm 2022 Jun 24:1-9. Epub 2022 Jun 24.

Centre for Ophthalmic Specialized Care, Lausanne, Switzerland.

Purpose: We investigated efficacy and safety of adalimumab (ADA) treatment for exacerbation or recurrence of Vogt-Koyanagi-Harada (VKH) patients.

Methods: Medical records of 70 VKH patients who received ADA treatment for more than 6 months were retrospectively investigated.

Results: The mean age of VKH patients was 54. Read More

View Article and Full-Text PDF

The Link between Cutaneous Inflammation and Cognitive Impairment.

J Eur Acad Dermatol Venereol 2022 Jun 24. Epub 2022 Jun 24.

Dermatology Hospital, Southern Medical University, Guangdong, 510091, China.

Cognitive impairment is a symptom of neurological disorders, including dementia and Alzheimer's disease; and mild cognitive impairment can be a precursor of both disorders. Aged humans and animal models with other systemic disorders, such as cardiovascular diseases and diabetes, display a higher incidence of cognitive decline. Epidemiological studies have shown that the incidence of cognitive impairment also is higher in subjects with certain inflammatory skin disorders, including psoriasis and chronic eczematous dermatitis. Read More

View Article and Full-Text PDF

ROS-sensitive calcipotriol nano-micelles prepared by methoxypolyethylene glycol (mPEG) - modified polymer for the treatment of psoriasis.

Drug Deliv 2022 Dec;29(1):1903-1913

School of Pharmacy, Weifang Medical University, Weifang, China.

Oxidative stress due to excessive reactive oxygen species (ROS) production in the skin microenvironment is one of the main mechanisms in psoriasis pathogenesis. A nano drug delivery system based on ROS-responsive release can enhance drug release at the target site. In this study, a ROS-sensitive material methoxypolyethylene glycol-thioether-thiol (mPEG-SS) was synthesized using mPEG as the parent structure with sulfide structural modification. Read More

View Article and Full-Text PDF
December 2022

Intravenous AsO as a promising treatment for psoriasis - an experimental study in psoriasis-like mouse model.

Immunopharmacol Immunotoxicol 2022 Jun 24:1-46. Epub 2022 Jun 24.

Department of Environmental Health and Toxicology, School of Public Health, Dalian Medical University, Dalian, Liaoning, China 116044.

Objective: To evaluate the efficacy and mechanistic bases of the intravenous injection of arsenic trioxide at clinical-relevant doses for treating imiquimod-induced psoriasis-like mouse model.

Methods: After inducing psoriasis-like skin lesions on the back of mice with imiquimod, mice in each group were injected with a clinical dose of arsenic trioxide through the tail vein. The changes in the gene expression, protein expression and distribution of relevant inflammatory factors were evaluated in the inflicted skin area, for mechanisms underlying the efficacy of intravenous AsO intervention. Read More

View Article and Full-Text PDF

Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).

J Eur Acad Dermatol Venereol 2022 Jun 24. Epub 2022 Jun 24.

Dermatology and Venereology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden; Dermatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Background: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. Read More

View Article and Full-Text PDF

[Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2-Management of Special Populations, Patients With Comorbid Conditions, and Risk.

Actas Dermosifiliogr 2022 Jun 21;113(6):T583-T609. Epub 2022 May 21.

Servicio de Dermatología, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain.

Background And Objectives: Since its inception, the Psoriasis Group (GPs) of the Spanish Academy of Dermatology and Venereology (AEDV) has worked to continuously update recommendations for the treatment of psoriasis based on the best available evidence and incorporating proposals arising from and aimed at clinical practice. An updated GPs consensus document on the treatment of moderate to severe psoriasis was needed because of changes in the treatment paradigm and the approval in recent years of a large number of new biologic agents.

Methodology: The consensus document was developed using the nominal group technique complemented by a scoping review. Read More

View Article and Full-Text PDF

Treatment Opportunities and Technological Progress Prospective for Acne Vulgaris.

Curr Drug Deliv 2022 Jun 23. Epub 2022 Jun 23.

ISF College of Pharmacy, Moga, Punjab, 142001, India.

A frequent inflammatory pilosebaceous disorder that affects 80-90% of teenagers, acne vulgaris is still a concern for dermatologists and other doctors in the field of medicine. Acne has a significant psychosocial impact and is responsible for a bigger worldwide burden of disease than psoriasis, cellulitis, and melanoma, as measured by age-standardized disability-adjusted life years. Patients may experience psychological problems as well as severe skin scars as a result of the condition. Read More

View Article and Full-Text PDF

PSSD and biologic therapy: Real-life data in 417 patients with moderate to severe psoriasis.

Rev Recent Clin Trials 2022 Jun 23. Epub 2022 Jun 23.

Dermatology Unit "D. Innocenzi", Polo Pontino, Sapienza University of Rome, Italy.

Background: Psoriasis is a chronic relapsing immune-mediated disease leading to a strong impact on patient's quality of life. The treatment of psoriasis has undergone a revolution with the advent of biologic therapies. Currently, Psoriasis Area and Severity Index [PASI] and Dermatology Life Quality Index [DLQI] scores are in use to assess the overall severity of pathology. Read More

View Article and Full-Text PDF

Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.

Int J Cancer 2022 Jun 23. Epub 2022 Jun 23.

Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.

Deucravacitinib, a novel, selective inhibitor of TYK2 is currently under review at the FDA and EMA for treatment of moderate-to-severe plaque psoriasis. It is unclear whether recent safety concerns (ie, elevated rates of lung cancer and lymphoma) related to similar medications (ie, other JAK inhibitors) are shared with this novel TYK2 inhibitor. We used a partial loss-of-function variant in TYK2 (rs34536443), previously shown to protect against psoriasis and other autoimmune diseases, to evaluate the potential effect of therapeutic TYK2 inhibition on risk of lung cancer and non-Hodgkin lymphoma. Read More

View Article and Full-Text PDF

Long-term efficacy of biologic treatment for psoriasis after COVID-19 infection.

Clin Exp Dermatol 2022 Jun 23. Epub 2022 Jun 23.

First Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, Greece.

View Article and Full-Text PDF

Modulation of psoriatic-like skin inflammation by traditional Indian medicine Divya-Kayakalp-Vati and Oil through attenuation of pro-inflammatory cytokines.

J Tradit Complement Med 2022 Jul 20;12(4):335-344. Epub 2021 Sep 20.

Drug Discovery and Development Division, Patanjali Research Institute, NH-58, Haridwar, 249405, Uttarakhand, India.

Background And Aim: Psoriasis (Ps) is a chronic skin inflammatory disorder, that progresses to scaly-red dermal plaque formations associated with inflammation. Divya-Kayakalp-Vati (DKV) and Divya-Kayakalp-Oil (DKO) are traditional Ayurveda herbo-mineral formulations, that are prescribed for the treatment of inflammatory dermal ailments. In the present study, we evaluated the efficacy of Divya-Kayakalp-Vati and Divya-Kayakalp-Oil (DKV-O) combined treatment in ameliorating Ps-like skin inflammation under and conditions. Read More

View Article and Full-Text PDF

Influence of Oil Polarity and Cosurfactants on the Foamability of Mono- and Diacylphosphatidylcholine Stabilized Emulsions.

Pharmaceutics 2022 Jun 7;14(6). Epub 2022 Jun 7.

Department of Pharmaceutical Technology, Eberhard Karls University, Auf der Morgenstelle 8, 72076 Tuebingen, Germany.

Foam formulations are safe and effective therapy options for the treatment of chronic skin conditions that require the application of a topical formulation to delicate skin areas, such as scalp psoriasis or seborrheic dermatitis. This study focused on the development of foamable emulsions based on aqueous phospholipid blends. The effects of cosurfactants (nonionic Lauryglucoside (LG); zwitterionic Lauramidopropyl betaine (LAPB)), as well as of oil phases of different polarities, namely paraffin oil (PO), medium-chain triglycerides (MCT) and castor oil (CO), were investigated. Read More

View Article and Full-Text PDF

Structural and Functional Validation of a Full-Thickness Self-Assembled Skin Equivalent for Disease Modeling.

Pharmaceutics 2022 Jun 7;14(6). Epub 2022 Jun 7.

Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13497, Korea.

Recently, various types of in vitro-reconstructed 3D skin models have been developed for drug testing and disease modeling. Herein, we structurally and functionally validated a self-assembled reconstructed skin equivalent (RSE) and developed an IL-17a-induced in vitro psoriasis-like model using a self-assembled RSE. The tissue engineering approach was used to construct the self-assembled RSE. Read More

View Article and Full-Text PDF

Antipsoriatic Potential of Quebecol and Its Derivatives.

Pharmaceutics 2022 May 26;14(6). Epub 2022 May 26.

Centre de Recherche en Organogénèse Expérimentale de L'Université Laval/LOEX, Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec-Université Laval, Quebec, QC GIJ 1Z4, Canada.

Psoriasis is a chronic inflammatory skin disease mainly characterized by the hyperproliferation and abnormal differentiation of the epidermal keratinocytes. An interesting phenolic compound, namely quebecol (2,3,3-tri-(3-methoxy-4-hydroxyphenyl)-1-propanol) (compound , CPD1), was isolated from maple syrup in 2011 and was recently synthesized. Quebecol and its derivatives ethyl 2,3,3-tris(3-hydroxy-4-methoxyphenyl)propenoate (compound , CPD2) and bis(4-hydroxy-3-methoxyphenyl)methane (compound , CPD3) have shown antiproliferative and anti-inflammatory potential, making them promising candidates for the treatment of psoriasis. Read More

View Article and Full-Text PDF

Oral Administration of East Asian Herbal Medicine for Inflammatory Skin Lesions in Plaque Psoriasis: A Systematic Review, Meta-Analysis, and Exploration of Core Herbal Materials.

Nutrients 2022 Jun 12;14(12). Epub 2022 Jun 12.

Department of Herbal Pharmacology, College of Korean Medicine, Gachon University, 1342 Seongnamdae-ro, Sujeong-gu, Seongnam 13120, Korea.

Psoriasis is an inflammatory autoimmune skin disease with various clinical manifestations. The aim of this review was to systematically evaluate the efficacy and safety of oral administration of East Asian herbal medicine (EAHM) for inflammatory skin lesions in psoriasis and to explore core herbal materials for drug discovery. A comprehensive search was conducted in 10 electronic databases for randomized controlled trials from their inception until 29 July 2021. Read More

View Article and Full-Text PDF

Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data.

Pnina Fishman

Molecules 2022 Jun 8;27(12). Epub 2022 Jun 8.

Can-Fite BioPharma Ltd., 10 Bareket St., Petah Tikva 49170, Israel.

The A3 adenosine receptor (A3AR) is overexpressed in pathological human cells. Piclidenoson and namodenoson are A3AR agonists with high affinity and selectivity to A3AR. Both induce apoptosis of cancer and inflammatory cells via a molecular mechanism entailing deregulation of the Wnt and the NF-κB signaling pathways. Read More

View Article and Full-Text PDF

Botulinum Toxin Use for Modulating Neuroimmune Cutaneous Activity in Psoriasis.

Medicina (Kaunas) 2022 Jun 16;58(6). Epub 2022 Jun 16.

Department of Physical and Rehabilitation Medicine-"Elias" Emergency University Hospital, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Psoriasis is a complex immune-mediated inflammatory disorder that generates enormous interest within the scientific communities worldwide, with new therapeutic targets being constantly identified and tested. Despite the numerous topical and systemic medications available for the treatment of psoriasis, alternative therapies are still needed for the optimal management of some patients who present with localized, resistant lesions. Novel insights into the contribution of cutaneous neurogenic inflammation in the pathogenesis of psoriasis have yielded exciting new potential roles of nerve-targeting treatments, namely botulinum toxin type A (BoNT-A), for the management of this disease. Read More

View Article and Full-Text PDF

Oversight and Management of Women with Psoriasis in Childbearing Age.

Medicina (Kaunas) 2022 Jun 9;58(6). Epub 2022 Jun 9.

Department of Family Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Psoriasis is a complex disease with many associated comorbidities, all of which have a negative impact on a patient's personal, social, and sexual life. There are some unique considerations in the effects of this disease among women. The average age of diagnosis in women with psoriasis is 28 years, and this onset corresponds to the fertile life of women. Read More

View Article and Full-Text PDF

Immuno-Pathogenesis of Chronic Inflammatory Skin Diseases: Novel Molecular Targets and Biomarkers.

Life (Basel) 2022 Jun 15;12(6). Epub 2022 Jun 15.

Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, SA, Italy.

Chronic inflammation has a crucial pathogenetic role in many diseases, including cutaneous chronic inflammatory disorders, such as psoriasis, atopic dermatitis, hidradenitis suppurativa, and chronic urticaria [... Read More

View Article and Full-Text PDF

Role of Yes-Associated Protein in Psoriasis and Skin Tumor Pathogenesis.

J Pers Med 2022 Jun 16;12(6). Epub 2022 Jun 16.

State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.

Psoriasis and skin tumors (such as basal cell carcinoma, squamous cell carcinoma, and melanoma) are chronic diseases that endanger physical and mental health, and yet the causes are largely unknown and treatment options limited. The development of targeted drugs requires a better understanding of the exact pathogenesis of these diseases, and Yes-associated protein (YAP), a member of the Hippo signaling pathway, is believed to play an important role. Psoriasis and skin tumors are characterized by excessive cell proliferation, abnormal differentiation, vasodilation, and proliferation. Read More

View Article and Full-Text PDF

Metabolic Profiling in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: Elucidating Pathogenesis, Improving Diagnosis, and Monitoring Disease Activity.

J Pers Med 2022 Jun 2;12(6). Epub 2022 Jun 2.

Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, University Hospital of Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

Immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (Ps), represent autoinflammatory and autoimmune disorders, as well as conditions that have an overlap of both categories. Understanding the underlying pathogeneses, making diagnoses, and choosing individualized treatments remain challenging due to heterogeneous disease phenotypes and the lack of reliable biomarkers that drive the treatment choice. In this review, we provide an overview of the low-molecular-weight metabolites that might be employed as biomarkers for various applications, e. Read More

View Article and Full-Text PDF

Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF).

Int J Mol Sci 2022 Jun 17;23(12). Epub 2022 Jun 17.

Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.

PEL is a rare B cell lymphoma associated with KSHV that mainly arises in immune-deficient individuals. The search for new drugs to treat this cancer is still ongoing given its aggressiveness and the poor response to chemotherapies. In this study, we found that DMF, a drug known for its anti-inflammatory properties which is registered for the treatment of psoriasis and relapsing-remitting MS, could be a promising therapeutic strategy against PEL. Read More

View Article and Full-Text PDF

Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time.

Int J Mol Sci 2022 Jun 14;23(12). Epub 2022 Jun 14.

Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, SI-1000 Ljubljana, Slovenia.

Psoriasis is a chronic systemic inflammatory disease. Due to systemic inflammation, it is associated with many comorbidities. Among them, cardiovascular diseases represent the most common causes of morbidity and mortality in this population. Read More

View Article and Full-Text PDF

Altered Distribution and Expression of Syndecan-1 and -4 as an Additional Hallmark in Psoriasis.

Int J Mol Sci 2022 Jun 10;23(12). Epub 2022 Jun 10.

Biohellenika Biotechnology Company, Leoforos Georgikis Scholis 65, 55535 Thessaloniki, Greece.

Syndecans act as independent co-receptors to exert biological activities and their altered function is associated with many pathophysiological conditions. Here, syndecan-1 and -4 were examined in lesional skin of patients with psoriasis. Immunohistochemical staining confirmed altered syndecan-1 distribution and revealed absence of syndecan-4 expression in the epidermis. Read More

View Article and Full-Text PDF

Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases.

Biology (Basel) 2022 May 25;11(6). Epub 2022 May 25.

Department of Dermatology, 'Elias' Emergency University Hospital, 011461 Bucharest, Romania.

Psoriasis is a chronic multisystem inflammatory disease associated with a plethora of comorbidities including metabolic syndrome, cardiovascular disease, hypertension, diabetes, hyperlipidemia, obesity, anxiety, depression, chronic kidney disease, and malignancy. Advancement in unveiling new key elements in the pathophysiology of psoriasis led to significant progress in the development of biologic agents which target different signaling pathways and cytokines involved in the inflammatory cascade responsible for the clinical manifestations found in psoriasis. Currently available novel therapeutic options for moderate-severe psoriasis include tumor necrosis factor alpha inhibitors, inhibitors of the interleukin 17, and inhibitors of the interleukin 23. Read More

View Article and Full-Text PDF

Artificial intelligence for the automated single-shot assessment of psoriasis severity.

J Eur Acad Dermatol Venereol 2022 Jun 23. Epub 2022 Jun 23.

Department of Dermatology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Background: PASI score is globally used to assess disease activity of psoriasis. However, it is relatively complicated and time-consuming, and the score will vary due to the inconsistent subjectivity between dermatologists. Therefore, an AI system capable of assessing psoriasis severity will be useful. Read More

View Article and Full-Text PDF

J Dermatolog Treat 2022 Jun 23:1-29. Epub 2022 Jun 23.

Eastern Virginia Medical School Department of Dermatology.

Background: Associations between cardiometabolic multimorbidity and response to therapy in psoriasis are unknown.

Objective: Determine the associations of multimorbidity with response to biologic treatment in psoriasis patients.

Methods: CorEvitas Psoriasis Registry participants who initiated biologic therapy and had 6-months follow-up were stratified by 0, 1, 2+ comorbidities (diabetes, hypertension, hyperlipidemia). Read More

View Article and Full-Text PDF